SCHEMBL670066

SCHEMBL670066

O=C1C=c2cccnc2=NC1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.36
S100A4 P26447 2/20 0.34
CDC25B P30305 1/20 0.34
TDP2 O95551 2/20 0.33
NSD2 O96028 2/20 0.33
PAX8 Q06710 2/20 0.33
ABL1 P00519 1/20 0.33
PLCG1 P19174 1/20 0.33
CES1 P23141 1/20 0.33
RIN1 Q13671 1/20 0.33
TGM2 P21980 1/20 0.33
PADI1 Q9ULC6 1/20 0.33
PADI3 Q9ULW8 1/20 0.33
PADI4 Q9UM07 1/20 0.33
PADI2 Q9Y2J8 1/20 0.33
MEN1 O00255 1/20 0.33
THRB P10828 1/20 0.33
BLM P54132 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL668836 0.79 BRD4 (0.38) BRD4S100A4CDC25BTDP2NSD2
SCHEMBL27713894 0.78 BRD4 (0.37) BRD4S100A4CDC25BTDP2NSD2
Hydrochloric Acid SCHEMBL27167121 0.78 BRD4 (0.37) BRD4S100A4CDC25BTDP2NSD2
Hydrochloric Acid SCHEMBL27167119 0.78 BRD4 (0.37) BRD4S100A4CDC25BTDP2NSD2
SCHEMBL10513637 0.71 BRD4 (0.38) BRD4TDP2NSD2PAX8ABL1
Quinoline SCHEMBL28279896 0.69 ALDH1A1 (0.50) MEN1KMT2ATDP1
SCHEMBL182548 0.68 MAPT (0.47) MEN1BLMKMT2A
SCHEMBL29548300 0.68 LMNA (0.47) MEN1BLMKMT2ATDP1
SCHEMBL1133597 0.68 TDP1 (0.37) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL8705259 0.68 S100A4 (0.38) S100A4CDC25BTDP2NSD2PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250221294-A1 POLYMER, ORGANIC SEMICONDUCTOR MATERIAL, STRETCHABLE POLYMER THIN FILM, AND ELECTRONIC DEVICE SAMSUNG ELECTRONICS CO., LTD. (KR) 2025-07-03 US disclosed
CN-119604539-A Antigen binding molecules with increased brain penetration and retention and methods of use thereof 中外制药株式会社 2025-03-11 CN disclosed
WO-2025036442-A1 METHOD FOR PREPARING PYRAZINONAPHTHYRIDINE DIONE COMPOUND, AND INTERMEDIATE THEREOF 劲方医药科技(上海)股份有限公司 2025-02-20 WO disclosed
CN-118871462-A Anti-interleukin-33 antibodies and uses thereof 基因泰克公司 2024-10-29 CN disclosed
CN-118401546-A Stabilized IL-18 polypeptides and uses thereof 基因泰克公司 2024-07-26 CN disclosed
CN-118369349-A Antibodies that bind to CD3 and PLAP 豪夫迈·罗氏有限公司 2024-07-19 CN disclosed
CN-118271445-A Antibodies that bind to CD3 豪夫迈·罗氏有限公司 2024-07-02 CN disclosed
CN-113621062-B Antibodies that bind to CD3 豪夫迈·罗氏有限公司 2024-07-02 CN disclosed
CN-113195056-B Antibodies that bind to CD3 豪夫迈·罗氏有限公司 2024-05-07 CN disclosed
CN-111212850-B Copy protection for antibodies 豪夫迈·罗氏有限公司 2024-04-16 CN disclosed
US-20150344476-A1 Naphthyridinedione derivatives NOVARTIS AG (CH) 2015-12-03 US disclosed
US-20150218164-A1 SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. 2015-08-06 US disclosed
US-20150218164-A1 SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. 2015-08-06 US disclosed
US-9073920-B2 Substituted dibenzonaphthyridines, pharmaceutical uses thereof and processes therfor PURDUE RESEARCH FOUNDATION (US) 2015-07-07 US disclosed
EP-2877469-A1 SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS HIV INTEGRASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-06-03 EP disclosed
EP-2877469-A1 SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS HIV INTEGRASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-06-03 EP disclosed
WO-2014018449-A1 SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-01-30 WO disclosed
WO-2014018449-A1 SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-01-30 WO disclosed
US-20130143878-A1 SUBSTITUTED DIBENZONAPHTHYRIDINES, PHARMACEUTICAL USES THEREOF AND PROCESSES THERFOR PURDUE RESEARCH FOUNDATION (US) 2013-06-06 US disclosed
WO-2012024437-A1 SUBSTITUTED DIBENZONAPHTHYRIDINES, PHARMACEUTICAL USES THEREOF AND PROCESSES THERFOR PURDUE RESEARCH FOUNDATION (US) 2012-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143878-A1 SUBSTITUTED DIBENZONAPHTHYRIDINES, PHARMACEUTICAL USES THEREOF AND PROCESSES THERFOR KRAS, QDPR, BTD BRD4 289/4885S100A4 3031/4885CDC25B 3955/4885
US-20150218164-A1 SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS HIV INTEGRASE INHIBITORS SAMHD1, ENTPD5, DUT BRD4 390/4885S100A4 4750/4885CDC25B 583/4885
US-20150344476-A1 Naphthyridinedione derivatives NPM1, CYP2D6, NQO1 BRD4 458/4885S100A4 1601/4885CDC25B 1348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.